TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04386993

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).
Study: NCT04571944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant administered at a dose of 15 mg QD via oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suvorexant-matching placebo administered QD via oral tablet
Study: NCT04040569

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiomics on MRI
Description: Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence.
Study: NCT02967991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided liver biopsy
Description: Endoscopic ultrasound guided liver biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided liver biopsy
Description: Endoscopic ultrasound guided liver biopsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy
Description: Endoscopic ultrasound guided liver biopsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy
Description: Endoscopic ultrasound guided liver biopsy
Study: NCT03197298

Intervention type: DRUG
Intervention: Clopidogrel

Intervention type: DRUG
Intervention: Ticagrelor
Study: NCT01254136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB007839 300mg BID
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Study: NCT03486912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days.
Study: NCT04298021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: * In AZD6738+Durvalumab cohort~  - AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: * In AZD6738+Durvalumab cohort~  - AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg iv on D1 Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg bid on D1-28 Every 4 weeks
Study: NCT02164123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Description: Experimental group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Mobilization II
Description: Active comparator group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study: NCT02621320

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: alcohol-based solution 1.3ml daily over a period of 12 weeks.
Study: NCT02104050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: 6 mL of Placebo Gel administered TID for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLT1177 Gel
Description: 6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
Study: NCT02117947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help control
Description: This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
Study: NCT01436851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Storage mite allergen extracts
Description: Nasal provocation with increasing doses of storage mite allergen extracts
Study: NCT00440999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study: NCT03447808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03486912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days.
Study: NCT03875378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Description: Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo weekly patch
Study: NCT04081493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restricted exercise
Description: Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises
Study: NCT03932344

Intervention type: DRUG
Intervention: Anakinra
Description: Anakinra according to prescription
Study: NCT01856270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
Study: NCT02933008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aNMT Biofeedback
Description: aNMT utilizes well-established visual feedback strategies to promote efficient, rapid and robust learning of complex movements. Athletes can discover how to move to create the desired feedback, even without explicit, conscious knowledge of how their movements relate to the visual pattern. aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Biofeedback
Description: Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular Training
Description: Participants will complete a 12-session, pre-season training program, over 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Participants will complete a 12-session, pre-season training program, over 6 weeks.
Study: NCT06047210

Intervention type: OTHER
Intervention: Blood Draws Data Collection

Intervention type: OTHER
Intervention: Blood Draws Data Collection
Study: NCT03063892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Description: Tranexamic acid is an antifibrinolytic used to control bleeding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution is used as the placebo comparator
Study: NCT03675126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-5051
Description: SRP-5051 administered as an IV infusion.
Study: NCT03302325

Intervention type: PROCEDURE
Intervention: research blood draws
Description: Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).
Study: NCT03134196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Masked Placebo
Description: Oral Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Masked Oral Valacyclovir
Description: Oral Valacyclovir 1000 mg/day
Study: NCT03026062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT03521570

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Undergo intensity-modulated radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03593525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK
Description: see above
Study: NCT01210313

Intervention type: OTHER
Intervention: Physical exercise
Description: Defined exercise program
Study: NCT03496844

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: F-18 fluciclovine-PET/CT scan
Description: PET/CT imaging with F-18 fluciclovine
Study: NCT03193840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior wall osteotomy
Description: posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
Study: NCT01901445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational action with focal group
Study: NCT03447808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01039792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl B12
Description: 75 µg/Kg subcutaneously injected once every 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04160117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: p.o. twice daily for 10 days after catheter ablation for atrial fibrillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
Study: NCT04603846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-L1 antibody
Description: Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin bound paclitaxel
Description: Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
Study: NCT02439723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study: NCT03131154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Solution (0.5%)
Description: ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of ADX-102 Ophthalmic Solution
Description: Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
Study: NCT03394729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis tablet to limit dental biofilm
Description: The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xilytol tablet to limit dental biofilm
Description: The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
Study: NCT04280341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC48-ADC in combinaton with JS001
Description: The study has 2 parts which include dose escalation phase and dose extension phase.~Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with HER2-Positive Advanced Malignant Solid Tumors sequentially at escalating doses of 2.0mg/kg and 2.5mg/kg to RC48-ADC and JS001 is fixed dose of 3.0mg/mg
Study: NCT04298697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Description: TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Description: TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Description: TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Description: TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
Study: NCT03594513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCAF
Description: Periodontal surgical technique to treat gingival recessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCAF
Description: Periodontal surgical technique to treat gingival recessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PR
Description: Restorative procedure to treat tooth structure loss.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PR
Description: Restorative procedure to treat tooth structure loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG
Description: Autogenous graft harvested from palate placed in the surgical site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XMD(Mucoderm®)
Description: Xenogenous graft placed in the surgical site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium dipyrone
Description: All participants were instructed to take 500 mg sodium dipyrone just in case of pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium dipyrone
Description: All participants were instructed to take 500 mg sodium dipyrone just in case of pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine rinse
Description: All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine rinse
Description: All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
Study: NCT01808755

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D Mannose
Description: 1 gr. every 8 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D Mannose
Description: 1 gr. every 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim/sulfamethoxazole
Description: one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim/sulfamethoxazole
Description: one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
Study: NCT04242953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCO-120
Description: Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: Part A: single oral administration~Part C: multiple oral administration (14 day dosing)
Study: NCT03167749

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory test
Description: Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory test
Description: Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
Study: NCT03735303

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 group
Description: VD3 50000 IU/ week for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 3 FA group
Description: omega 3 FA group 300 mg once daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 and omega- 3FA group
Description: 50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: no intervention was given
Study: NCT00352768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate
Description: Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo